Since c-Abl activation is linked to many neurodegenerative disorders including Alzheimer’s disease (39) and amyotrophic lateral sclerosis (40), Radotinib HCl may also have broad clinical implications. This evidence concerns the gene ABL1 and early-onset autosomal dominant Alzheimer disease.